Research: The Effects of Higher Doses and More Frequent use of Evolocumab in Diabetics
Statin therapy is the most efficient treatment option for heart disease due to its regressional and anti-inflammatory effect on plaque formation in the arteries and decrease in LDL-cholesterol. Higher and more frequent use of statin therapy has shown to cause increases in blood glucose, furthermore causing an increased risk of developing new-onset diabetes. Evolocumab, a type of PCSK9 inhibitor, has shown to be effective in lowering LDL-cholesterol levels without increasing blood glucose, making it a safer treatment option for heart disease in diabetics opposed to statin therapies. The effects of higher and more frequent use of evolocumab on blood glucose and risk of new-onset diabetes is yet to be known. In a 2017 study by Leiter et al., diabetics were given 140 mg of evolocumab every 2 weeks and had their blood glucose and cholesterol levels monitored. Diabetic lab rats are to be put on 140 mg of evolocumab every week, opposed to every 2 weeks, and have their blood glucose and cholesterol levels checked consistently to check for any fluctuations. The subjects are to have any plaque formation or regression monitored using a Transtail Artery Access Catheter Angiogram every 6 months to test the full efficacy level of evolocumab taken more frequently in higher doses. When evolocumab was taken at 140 mg every 2 weeks, participants experienced lowered LDL cholesterol levels by 57% at 48 weeks but no change in blood glucose. Subjects taking evolocumab at 140mg weekly are expected to experience the same effects. Taking higher doses of evolocumab more frequently may be beneficial towards patients treating heart disease.